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SUMMARY – Mesonephric adenocarcinoma is a rare variant of cervical adenocarcinoma. We 
present a case of mesonephric adenocarcinoma of endocervix with cervical and vaginal lobular meso-
nephric hyperplasia in a 57-year-old woman. Vaginal bleeding persisting for 12 months was the only 
symptom. Histopathologic fi ndings and characteristic immunophenotype are crucial for the diagnosis. 
Th e tumor was composed of papillary formation with a central fi brovascular stroma, villoglandular and 
densely compact tubular structures containing intraluminal eosinophilic secretion, and coated with 
one or more rows of cylindrical atypical epithelial cells. Th ere were 30 pathologic mitotic shapes found 
per 10 HPF. Th e tumor invaded nearly full-thickness of cervical stroma with positive lymphovascular 
space invasion and clear margins. Th e case demonstrated characteristic cytokeratin 7, vimentin and 
epithelial membrane antigen positivity and high Ki-67 proliferation index (60%). Estrogen receptors, 
progesterone receptors and carcinoembryonic antigen were negative. Intratubular lumen secretion was 
periodic acid-Schiff  positive with periodic acid-Schiff  negative carcinoma cells. Diff erential diagnoses 
include adenoma malignum, well-diff erentiated villoglandular adenocarcinoma, endometrioid adeno-
carcinoma, serous adenocarcinoma, mesonephric adenocarcinoma with a sarcomatous component, 
clear-cell carcinoma and mesonephric hyperplasia. Radical hysterectomy with bilateral salpingo-oo-
phorectomy, pelvic and para-aortic lymphadenectomy was performed. Th ree years after the surgery, 
the patient remains well. Th ere has not been any evidence of local or distant recurrence. Th ere are no 
specifi c recommendations for the treatment of this rare disease. It remains uncertain whether surgical 
approach is suffi  cient or the treatment should include additional radio/chemotherapy.
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Introduction
Malignant mesonephric tumors are derived from 
remnants of the mesonephric (wollfi an) ducts. In the 
absence of testosterone, the mesonephric ducts regress. 
Remnants may persist as the epoophoron, Skene’s 
glands and Gartner’s duct. Th ey are usually located in 
the uterine cervix, lateral wall of the vagina, broad liga-
ment, mesosalpinx and in the ovarian hilium1. Meso-
nephric duct remnants are found in 10%-22% of adult 
uterine cervices2,3. Hyperplasia of these remnants is a 
benign lesion that is almost always discovered inciden-
tally in cone biopsy or hysterectomy specimens1,4. Ma-
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lignant mesonephric tumor, arising from mesonephric 
duct hyperplasia or mesonephric remnants, is an ex-
tremely rare variant of cervical adenocarcinoma5, with 
35 cases reported in the literature4,6,7. We present a case 
of mesonephric adenocarcinoma of uterine cervix as-
sociated with lobular mesonephric hyperplasia. Clini-
cal, pathological and immunohistochemical character-
istics are discussed.
Case Report
A 57-year-old postmenopausal woman presented 
for vaginal bleeding persisting for 12 months. Endo-
cervical curettage and cervical adenocarcinoma diag-
nosis were made at an external institution. Her previ-
ous medical history was not signifi cant and included 
only hypertension. Physical examination revealed ap-
propriate external genitals, medium large vagina with 
some active bleeding from the uterine cervix. Th ere 
were no signs of infection, infl ammation or other ab-
normalities of uterine cervix. Uterus was of normal 
size, movable and painless. Bilateral parametria were 
free. Transvaginal ultrasonography showed a 5.6x4.5 
cm solid mass in the uterine corpus and 1.9x2.7 cm 
hyperechoic formation in the uterine cervix. Magnetic 
resonance imaging (MRI) showed a uterine cervical 
mass measuring 4 cm in diameter. Th ere was no sig-
nifi cant lymphadenopathy. Th e patient underwent 
radical hysterectomy with bilateral salpingo-oopho-
rectomy, pelvic and para-aortic lymphadenectomy. 
Postoperative period passed without any complica-
tions. Histopathologic and immunohistochemical 
analysis confi rmed the diagnosis of mesonephric ade-
nocarcinoma of uterine cervix, lobular mesonephric 
hyperplasia, adenomyosis and leiomyoma of the uter-
us. Th e macroscopic intersection of the hysterectomy 
specimen showed a soft tumor mass measuring 5.5x4 
cm in the cervix and lower uterine segment. Th e tumor 
was composed of papillary formation with central fi -
brovascular stroma (Fig. 1), villoglandular and densely 
compact tubular structures containing intraluminal 
eosinophilic secretion, and coated with one or more 
rows of cylindrical atypical epithelial cells with vesicu-
lar nuclei which were interspersed and had the appear-
ance of ground glass. Th ere were 30 pathologic mitotic 
shapes found per 10 high power fi elds (HPF). Th e tu-
mor invaded nearly full-thickness of cervical stroma 
with positive lymphovascular space invasion and clear 
margins. In the adjacent area of adenocarcinoma, lobu-
lar mesonephric hyperplasia was observed (Fig. 2). Th e 
hyperplastic mesonephric tubules were also found in 
fornices of the vagina, also containing intraluminal eo-
sinophilic secretion. Compared to adenocarcinoma, 
there was no cytologic atypia.
Immunohistochemically, neoplastic cells were dif-
fusely positive for cytokeratin 7, vimentin, epithelial 
membrane antigen (EMA), and focally positive for 
p53. Th e adenocarcinoma component was negative for 
estrogen receptors (ER), progesterone receptors (PR), 
and carcinoembryonic antigen (CEA). Proliferation 
Fig. 1. Mesonephric adenocarcinoma composed of 
papillary formation with central fi brovascular stroma.
Fig. 2. Lobular mesonephric hyperplasia.
M. Puljiz et al. Mesonephric adenocarcinoma of endocervix
328 Acta Clin Croat, Vol. 55, No. 2, 2016
index Ki-67 was 60%. Th e intratubular lumen secre-
tion was periodic acid-Schiff  (PAS) positive, while 
that stain was absent in the adenocarcinoma cells. 
Based on these morphological and immunohisto-
chemical features, the diagnosis of mesonephric ade-
nocarcinoma, International Federation of Gynecology 
and Obstetrics (FIGO) IB2, with lobular mesonephric 
hyperplasia was confi rmed. Para-aortic (n=12) and 
pelvic (n=32) lymph nodes were negative for metasta-
sis. Th e patient has had regular checkups. To date, 
three years after the surgery, the patient remains well. 
Th ere has not been any evidence of local or distant re-
currence.
Discussion
Proliferative mesonephric lesions are extremely 
rare. Our patient was aged 57, and according to Anag-
nostopoulos et al.7, the mean age of patients with me-
sonephric adenocarcinomas of uterine cervix was 50.7 
years, age range between 24 and 73 years. Usually, most 
cases were diagnosed at an early stage of the disease, 
FIGO IB, presenting with abnormal vaginal bleeding, 
pelvic pain, dyspareunia, uterine prolapse or abnormal 
Pap smear6-8. In this particular case, the disease was 
diagnosed at an early stage, more precisely FIGO IB2. 
Abnormal vaginal bleeding was the only symptom. 
Th e etiology of mesonephric adenocarcinoma is not 
related to the human papillomavirus8.
Th e combination of histopathologic and immuno-
histochemical analysis of tumor tissue is crucial in dif-
ferential diagnosis of most cervical glandular lesions. 
Mesonephric adenocarcinomas of uterine cervix, 
which are presumed to arise from mesonephric hyper-
plasia or mesonephric remnants, are characterized by 
morphological diversity and an unusual appearance6. 
Diff erential diagnoses include adenoma malignum, 
well-diff erentiated villoglandular adenocarcinoma, en-
dometrioid adenocarcinoma, serous adenocarcinoma, 
mesonephric adenocarcinoma with a sarcomatous 
component, clear-cell carcinoma and mesonephric hy-
perplasia6,7,9. In almost all cases reported in the litera-
ture, mesonephric hyperplasia classifi ed as diff use me-
sonephric hyperplasia, ductal mesonephric hyperplasia 
and lobular mesonephric hyperplasia was observed 
adjacent to mesonephric adenocarcinoma, especially 
lobular and diff use subtypes6. Th ese categories of me-
sonephric hyperplasia have no clinical signifi cance but 
they may be misinterpreted as premalignant or malig-
nant lesions and pathologists should be aware of this 
possibility4,10. In our case, lobular mesonephric hyper-
plasia was found next to the area of adenocarcinoma 
and also in fornices of the vagina, but compared to 
adenocarcinoma, there was no cytologic atypia. Th e 
diff use form of mesonephric hyperplasia may extend 
deeply into the cervical wall mimicking minimal de-
viation adenocarcinoma11.
Appropriate patient management requires correct 
classifi cation of mesonephric lesions. Th e histopatho-
logic characteristics of mesonephric adenocarcinoma 
that help diff erentiate these lesions from adenoma ma-
lignum are cytologic atypia and lack of intracytoplas-
mic mucin6. Th e presence of sarcomatous components 
is the key to carcinosarcoma diagnosis8. Only 16% of 
carcinosarcomas reported in the English literature 
were of mesonephric duct origin2. Th e typical histo-
logic features of clear-cell cytoplasm and hobnail cell 
pattern, and the presence of PAS positive intraluminal 
secretion with PAS positive intracytoplasmic globules 
direct us to the diagnosis of clear-cell carcinoma9. Th e 
absence of mesonephric hyperplasia is associated with 
endometrioid adenocarcinoma and clear-cell carcino-
ma6. Our case demonstrated characteristic cytokeratin 
7, vimentin and EMA positivity, high Ki-67 prolifera-
tion index (60%), negative ER, PR, CEA and PAS 
positive intraluminal secretion with PAS negative car-
cinoma cells. Recent reports showed that immunohis-
tochemical features of mesonephric adenocarcinoma 
included positivity for epithelial markers including 
pancytokeratin, CK7, CAM5.2 and EMA7,9. Vimen-
tin is positive in 70% and calretinin in 88% of cervical 
mesonephric adenocarcinoma, while CK20, ER, PR 
and CEA are usually negative7,9. Th is staining profi le is 
crucial in the diff erential diagnosis, especially with en-
dometrioid and other paramesonephric adenocarcino-
mas, with which it may be confused. Th e expression of 
p53 and/or CD10 is also useful in establishing the di-
agnosis of mesonephric neoplasm. CD10 has been 
suggested as a marker for all mesonephric lesions in 
the female genital tract, although there are cases of 
CD10 negative mesonephric adenocarcinomas report-
ed in the literature4,6,9. Most other benign endocervical 
glandular lesions are negative for CD104. A high Ki-
67 (>40%) proliferative index is a feature of malignant 
lesions12.
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Th ere are no defi nite recommendations for the 
treatment and follow up of this uncommon disease. 
According to the current guidelines for cervical adeno-
carcinoma, surgery should be the primary choice for 
localized disease13,14. Surgical treatment implies radical 
hysterectomy, pelvic lymphadenectomy and, for pa-
tients with larger tumors and/or positive pelvic lymph 
nodes, para-aortic lymphadenectomy13,14. According to 
Bagué et al.15, surgery alone should be the treatment of 
choice. In our case, surgery was the only treatment and 
three years thereafter, there has been no evidence of 
local or distant recurrence. Th e role of chemotherapy 
and radiotherapy is unclear; there is little evidence for 
their effi  cacy3. Postoperative radiotherapy decreases 
the risk of disease progression to stage IB cervical can-
cer, with doubtful impact on overall survival16. A re-
view of the literature showed that chemotherapy might 
be considered as palliative treatment in patients with 
recurrence3,17,18. According to Anagnostopoulos et al.7, 
the mean disease-free interval for stage IB disease is 
48.6 months, with recurrence rate of 23% after surgery 
as primary treatment.
Conclusion
Th is case report draws attention to the importance 
of considering mesonephric adenocarcinoma in the 
diff erential diagnosis of cervical carcinoma. Although 
this type of tumor is rare, it is necessary to defi ne spe-
cifi c recommendations for treatment, which would 
lead to better follow up and overall survival. Our case 
contributes to the scarce knowledge of this rare disease 
and can help in proposing the treatment and follow up 
guidelines.
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Sažetak
MEZONEFRIČKI ADENOKARCINOM ENDOCERVIKSA 
S LOBULARNOM MEZONEFRIČKOM HIPERPLAZIJOM: PRIKAZ SLUČAJA
M. Puljiz, D. Danolić, L. Kostić, I. Alvir, D. Tomica, I. Mamić, I. Vlastelica Munivrana, M. Puljiz, 
D. V. Vrdoljak i M. Perić Balja
Mezonefrički adenokarcinom je rijedak oblik adenokarcinoma vrata maternice. Prikazujemo slučaj pedesetsedmogodiš-
nje bolesnice s mezonefričkim adenokarcinomom vrata maternice, cervikalnom i vaginalnom lobularnom mezonefričkom 
hiperplazijom. Jedini simptom bilo je vaginalno krvarenje u trajanju od 12 mjeseci. Patohistološki nalaz i imunohistokemijska 
analiza ključni su u postavljanju konačne dijagnoze. Tumor je bio građen od papilarnih formacija s centralnom fi brovaskular-
nom stromom, viloglandularnih i gusto kompaktnih tubularnih struktura s eozinofi lnom intraluminalnom sekrecijom koje 
su obložene jednim ili više redova cilindričnih atipičnih epitelnih stanica. Naš slučaj je pokazao karakteristično pozitivan 
citokeratin 7, vimentin i epitelni membranski antigen, visok Ki-67 indeks proliferacije (60%). Estrogenski receptori, proge-
steronski receptori i karcinoembrijski antigen bili su negativni. Intratubularna sekrecija bila je PAS (engl. periodic acid-Schiff ) 
pozitivna, a stanice karcinoma bile su PAS negativne. Diferencijalna dijagnoza uključuje maligni adenom, dobro diferenci rani 
viloglandularni adenokarcinom, endometrioidni adenokarcinom, serozni adenokarcinom, mezonefrički adenokarcinom s 
komponentom sarkoma, karcinom svijetlih stanica i mezonefričku hiperplaziju. U bolesnice je učinjena radikalna histerekto-
mija s obostranom adneksektomijom, zdjelična i paraaortna limfadenektomija. Tri godine nakon operacije u bolesnice nema 
znakova lokalnog recidiva niti udaljenih metastaza. Zbog malog broja opisanih slučajeva ne postoje preporuke za liječenje 
ovoga rijetkog patohistološkog oblika bolesti.
Ključne riječi: Uterini cervikalni tumori – dijagnostika; Uterini cervikalni tumori – patologija; Uterini cervikalni tumori – 
kirurgija; Adenokarcinom – dijagnostika; Adenokarcinom – krirugija; Mezonefrom – dijagnostika; Mezonefrom – patologija; 
 Hiperplazija; Citodijagnostika; Vagina – patologija; Prikazi slučaja
